Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03769506 · ClinicalTrials.gov registry record · Phase 3
ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy
A Phase 3 study of Head and Neck Cancer, sponsored by Rakuten Medical.
- Active
- Registry status
- Phase 3
- Development phase
- 135
- Enrollment target
- 20
- Study locations
NCT03769506: Active Phase 3 study of Head and Neck Cancer, sponsored by Rakuten Medical.
NCT03769506 is a Phase 3 study of Head and Neck Cancer that is active but no longer recruiting, run by Rakuten Medical. The registered enrollment target is 135 participants, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (48% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03769506, a Phase 3 study of Head and Neck Cancer, is active but no longer recruiting, sponsored by Rakuten Medical.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 135 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 vs Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy
Primary Outcome
PFS, defined as the time from randomization to the first occurrence of disease progression (PD), as determined by the Central Radiographic Review according to RECIST 1.1 with modifications, or death from any cause, whichever occurs first.
Conditions Studied
Interventions
- COMBINATION_PRODUCT ASP-1929 Photoimmunotherapy
- DRUG Physician's Choice SOC
Study Locations (20)
Florida
- Cancer Clinic - Miami
- Cancer Clinic - Tampa
Pennsylvania
- Cancer Clinic 1 - Philadelphia
- Cancer Clinic 2 - Philadelphia
Gujarat
- Cancer Clinic - Vadodara
- Cancer Clinic - Vadodara
Other
- Cancer Clinic - Mumbai
- Cancer Clinic - Taichung
Georgia
- Cancer Clinic - Atlanta
Kentucky
- Cancer Clinic - Lexington
Texas
- Cancer Clinic - Houston
Kamataka
- Cancer Clinic - Bangalore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2019-05-09 |
| Est. Completion | 2025-12 |
| Phase | Phase 3 |
What the registry record for NCT03769506 still lists
NCT03769506 is an interventional study that assigns participants to a tested intervention. The registered 135 participants enrollment target is mid-sized for trials with a published cap, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (48% lower).
The record links to 1 condition, with Head and Neck Cancer appearing as the primary indexed condition, and to 2 interventions - of which ASP-1929 Photoimmunotherapy is the first listed.
NCT03769506 names 20 study sites across 16 states, led by Florida, Pennsylvania, Gujarat.
Frequently Asked Questions
What is clinical trial NCT03769506 about?
NCT03769506 is a clinical study titled "ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy". A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 vs Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy
What is the current status of trial NCT03769506?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 135 participants. The study started on 2019-05-09. Estimated completion is 2025-12.
What conditions does trial NCT03769506 study?
This clinical trial studies the following conditions: Head and Neck Cancer.
What interventions are being tested in trial NCT03769506?
The interventions under investigation include: ASP-1929 Photoimmunotherapy (COMBINATION_PRODUCT), Physician's Choice SOC (DRUG).
Who is sponsoring clinical trial NCT03769506?
This trial is sponsored by Rakuten Medical, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03769506 being conducted?
This trial has 20 study locations across Florida, Georgia, Kentucky, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03769506's enrollment target sits among peer trials
135 68th of 250 higher than 183 of 250 other Head and Neck Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Addressing Taste Dysfunction With Miraculin in Head and Neck Cancer Patients Receiving Radiation Therapy
RECRUITING · Phase 3
-
Tumescence in HNC Skin Graft Reconstruction
ACTIVE NOT RECRUITING · Phase 3
-
RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Controlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia
ACTIVE NOT RECRUITING · Phase 3
-
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
COMPLETED · Phase 3
-
Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00870129 · 135 participants · NA
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
- NCT03666000 · 135 participants · Phase 1
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- NCT04891510 · 135 participants · NA
A Comparative Analysis of REVOLVE, LipoGrafter, and Viality in Autologous Fat Grafting During Breast Surgery
- NCT05121051 · 135 participants · Phase 2
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI